Postdoctoral fellow at Harvard Medical School, is a chief physician, Dr., and doctoral supervisor.
Affiliated HospitalHuashan Hospital Affiliated to Fudan University
→
He currently serves as the director of the Antibiotics Research Institute at Huashan Hospital affiliated with Fudan University, the first chairman of the Chinese Society of Bacterial Infection and Drug Resistance Prevention and Control, a standing committee member of the Chinese Society of Infectious Diseases, vice chairman of the Infectious Diseases Professional Committee and the Fungal Diseases Professional Committee of the China Medical Education Association, a member of the Executive Committee of the International Society for Antimicrobial Chemotherapy, a Fellow of ESCMID, and a Fellow of ISAC. He graduated from Shanghai Medical University in 1997 with a PhD in Internal Medicine (Infectious Diseases) and completed postdoctoral research at Harvard Medical School (2001-2003). He has long been engaged in the diagnosis and treatment of infectious diseases, especially various bacterial and fungal infections, and the rational use of antimicrobial drugs. He led the CHINET National Bacterial Resistance Surveillance Network and pioneered multidisciplinary collaborative diagnosis and treatment of carbapenem-resistant organisms (CROs) in China. He is the chief scientist of the Ministry of Science and Technology's "973" Program, a Shanghai Leading Talent, an Outstanding Academic Leader in Shanghai, and a Leading Medical Talent in Shanghai. In 2025, research findings were published in Science Advances and eBioMedicine, a sub-journal of The Lancet, elucidating the formation and transmission mechanisms of carbapenem-resistant and highly virulent Klebsiella pneumoniae (CR-hvKP) and highly virulent carbapenem-resistant Klebsiella pneumoniae (hv-CRKP).